DJS-001

DJS-001 is a preclinical antibody therapeutic discovered using DJS Antibodies’ HEPTAD platform and classified as a G protein-coupled receptor (GPCR) modulator for inflammatory indications. Public pipeline summaries list DJS-001 as an antibody targeting an undisclosed GPCR implicated in inflammation, reflecting DJS Antibodies’ focus on generating monoclonal antibodies against difficult-to-drug transmembrane proteins such as GPCRs for chronic inflammatory diseases.[3][7] Detailed target identity, binding properties, and specific disease indications beyond a general role in inflammation have not yet been disclosed.